Bioline RX Ltd Sponsored ADR Forecast, price target & analysts
Bioline RX Ltd Sponsored ADR Target price 2025 - Analyst rating & recommendation
Bioline RX Ltd Sponsored ADR Classifications & Recommendation:
Bioline RX Ltd Sponsored ADR Price Target
| Target Price | $26.00 |
| Price | $4.69 |
| Potential |
454.37%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Bioline RX Ltd Sponsored ADR 2026 .
The average Bioline RX Ltd Sponsored ADR target price is $26.00.
This is
454.37%
register free of charge
$40.00
752.88%
register free of charge
$12.00
155.86%
register free of charge
|
|
| A rating was issued by 2 analysts: 2 Analysts recommend Bioline RX Ltd Sponsored ADR to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Bioline RX Ltd Sponsored ADR stock has an average upside potential 2026 of
454.37%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 28.94 | 2.58 |
| 502.92% | 91.07% | |
| EBITDA Margin | -64.37% | -402.53% |
| 92.65% | 525.29% | |
| Net Margin | -31.86% | -864.12% |
| 97.48% | 2,612.32% |
3 Analysts have issued a sales forecast Bioline RX Ltd Sponsored ADR 2025 . The average Bioline RX Ltd Sponsored ADR sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Bioline RX Ltd Sponsored ADR 2025 . The average Bioline RX Ltd Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $-18.6m | 55.71% |
|---|---|---|
| 2025 |
$-10.4m
44.18%
Unlock
|
|
EBITDA Margin
| 2024 | -64.37% | 92.65% |
|---|---|---|
| 2025 |
-402.53%
525.29%
Unlock
|
|
1 Analyst has issued a net profit forecast Bioline RX Ltd Sponsored ADR 2025 . The average Bioline RX Ltd Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.01 | -0.01 |
| 83.33% | 0.00% | |
| P/E | negative | |
| EV/Sales | 4.30 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
